Should You Buy Edwards Lifesciences Corp (EW) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who wants to act immediately. EW is sitting near support after a sharp drop, but technical momentum is still bearish, options volume is skewed heavily to puts (near-term caution), and the latest quarter showed a major profitability deterioration despite revenue growth. I would hold off buying today and reassess after the 2026-02-10 earnings release confirms margin/EPS stabilization.
Technical Analysis
Price/Trend: EW closed at 81.52 (-2.08%), trading slightly below the S1 support (81.879) and above the next support S2 (80.714). This is a “testing support” setup, but not yet a confirmed rebound.
Momentum: MACD histogram is negative (-0.212) and expanding lower, which points to a continuing downswing rather than a bottom.
RSI: RSI_6 at ~30.36 is near oversold territory (compressed/weak momentum), which can set up a bounce, but by itself isn’t a buy signal.
Moving averages: Converging MAs suggest the stock is in a transition zone, but with MACD weakening the near-term bias remains down.
Near-term pattern odds (model): Similar-pattern analysis implies modest upside next day (+1.82%) but negative bias over the next week (-2.15%) and month (-2.02%).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Ratings and price targets have been moving up, with multiple Buy/Overweight reiterations and at least one notable upgrade (TD Cowen to Buy) plus target raises (e.g., Stifel to $110, Goldman to $108, Barclays to $103, Citi to $101, JPMorgan to $100, Piper to $98). A few firms remain more neutral (e.g., Baird Neutral; Canaccord Hold with sub-$90 targets).
Wall Street pros view (bull case): EW is entering a renewed growth cycle driven by TAVR indication expansion, durability data, and newer therapy momentum (Evoque), supporting a path to sustained double-digit organic growth.
Wall Street cons view (bear case): Sector/policy overhangs were mentioned broadly (Medicare/ACA-related risks), and the company must demonstrate that profitability can track revenue again—especially given the sharp YoY EPS/net income decline in the latest provided quarter.
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 81.860
Current: 81.860
